TrovaGene (NASDAQ:TROV) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS

TrovaGene (NASDAQ:TROV) issued its quarterly earnings results on Thursday. The medical research company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.13, Fidelity Earnings reports. TrovaGene had a negative return on equity of 149.88% and a negative net margin of 3,424.46%. The firm had revenue of $0.05 million during the quarter.

Shares of NASDAQ TROV traded down $0.03 during trading hours on Friday, reaching $1.71. 179,500 shares of the stock were exchanged, compared to its average volume of 870,989. The firm has a market capitalization of $11.07 million, a price-to-earnings ratio of -0.21 and a beta of 0.25. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.20 and a current ratio of 3.20. TrovaGene has a 52 week low of $0.88 and a 52 week high of $9.65. The stock’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $2.24.

TROV has been the subject of a number of recent analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price objective on shares of TrovaGene in a research report on Thursday, October 3rd. Noble Financial reaffirmed a “buy” rating and issued a $23.00 price objective on shares of TrovaGene in a research report on Wednesday, October 2nd.

About TrovaGene

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

See Also: Arbitrage

Earnings History for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply